Format

Send to

Choose Destination
Med Clin (Barc). 2004 Nov 6;123(16):601-5.

[Impact of metabolic syndrome in the control of blood pressure and dyslipemia].

[Article in Spanish]

Author information

1
Unidad de Hipertensión Arterial y Riesgo Cardiovascular, Servicio de Medicina Interna, Hospital de Sagunto, Sagunto, Valencia, Spain.

Abstract

BACKGROUND AND OBJECTIVE:

The objective of the study was to assess the influence of metabolic syndrome (MS) in the control of blood pressure (BP) and dyslipemia.

PATIENTS AND METHOD:

A cross sectional study was performed with 1,320 (634 M and 686 F), 40.1 (13.3) years-old, BMI 29.8 (4.7) hypertensive non-diabetic patients. MS was diagnosed according to NCEP-ATP-III guidelines. Blood pressure control goal was BP < 140/90 mmHg. Coronary risk (CR) was calculated according to Framingham (low < 10%, intermediate 10-20% and high > 20% at 10 years). Goals of C-LDL levels were those of NCEP-ATP-III.

RESULTS:

461 (35%) patients had MS and the remaining 859 became controls. Patients with MS had higher initial levels of hypertension and were receiving more antihypertensive drugs: 2.1 [1.3] vs. 1.7 [1.3]; p < 0.001), yet the average systolic and diastolic BP achieved and the degree of control was similar in both groups 53% vs. 52%; (p = ns). Patients with MS had higher CR at ten years than controls (10.7 [8.3] vs. 7.9 [6.8], p < 0.001) but achieved the C-LDL goals at fewer proportions than controls (57% vs. 74%; p < 0.001). In a regression analysis, patients with MS had 26% less probabilities of achieving both goals (p < 0.001).

CONCLUSIONS:

Hypertensive patients with MS have higher CR, and need more antihypertensive drugs to achieve the same BP goals. Yet it is more difficult for them to achieve LDL cholesterol goals. Patients with MS remain a target for cardiovascular prevention.

PMID:
15546516
DOI:
10.1016/s0025-7753(04)74615-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center